At Boston Medical Center, the Center for Addiction Treatment for AdoLescent/Young adults who use SubsTances (CATALYST) program helps teens and young adults who use alcohol or drugs. Our team provides access to a wide range of services including primary care, harm reduction, assessment and treatment of substance use disorders, psychiatry, psychotherapy, and recovery support for patients through age 25 and their families.
Conditions We Treat
Treatments & Services
- Assessment, diagnosis, and treatment of substance use disorders (SUDs)
- Assessment, diagnosis and treatment of psychiatric disorders
- Primary care including HIV screening, Pre-exposure Prophylaxis, Hepatitis C screening and treatment, screening for other sexually transmitted infections, and family planning
- Overdose education and naloxone kits
- Parent guidance for families
- Additional support with navigation and recovery coaching
Patients can either receive primary care Boston Medical Center OR get a referral from their existing primary care provider. The CATALYST Clinic team can help patients schedule and establish primary care at BMC in addition to their substance use care/services if desired.
We are a multidisciplinary team consisting of physicians board certified addiction medicine and psychiatry, licensed clinical social workers, a nurse care manager with addiction certification, a patient navigator, recovery coaches, and a program manager. We offer evidence-based treatment and are adept at working with young patients who use substances. Our team based-care allows us to provide the best care for patients and their families creating a clear path to healthy lives.
Sarah Bagley, MD, Msc
Ashley Dortch, LICSW, LADC I
Nicollette Johnson, MPH
Elizabeth Paci, MD
Elizabeth Robinson, MSN, RN
Juliana Scherer, LICSW, MPH
Deric Topp, MPH
Amy Yule, MD
Residency and Fellowship Information
Addiction Medicine Fellowship
The mission of the Grayken Fellowship in Addiction Medicine is to train physician addiction medicine leaders in clinical care, research, education, public health, and advocacy to improve addiction care for people vulnerable to health inequities due to race, ethnicity, gender, poverty, age, disability or stigmatizing illness.
The Grayken Addiction Medicine Fellowship Program is a 1 or 2 year fellowship. There is also a 3-year combined Infectious Disease-Addiction Medicine Fellowship and a 2-year Fellowship in Maternal Health Addiction. Fellows are mentored by our multidisciplinary faculty from Internal Medicine, Infectious Disease, Emergency Medicine, Obstetrics & Gynecology and Addiction Psychiatry. The Grayken Fellowship in Addiction Medicine is accredited by the ACGME. Click here to learn more
Latest from HealthCity
Recovery coach Tyshaun Perryman shared a candid story of his own father's experience of civil commitment for substance use treatment.
Despite advice from medical groups, nearly two-thirds of patients studied didn't receive medication for opioid use disorder.
BMC experts testified in support of eliminating the requirement to report abuse and neglect for babies born with neonatal opioid withdrawal syndrome.
Clinicians who treat this population are in a unique position to advocate for partnerships between community entities and health centers.
Experts underline that early intervention and tailored services are necessary to prevent lifelong harm for this vulnerable age group.
New provider principles lay out how to treat patients according to their age-specific needs — and elevate national discussions on systemic changes.
Better health outcomes hinge on positive social support for young adults with SUD, but uninformed family members can unintentionally cause harm.
As the pandemic surges, the urgency of adjusting to find the most useful approach to SUD treatment in a critical population is growing.
Youth opioid overdose deaths increasingly involve cocaine and other substances rather than opioids alone, research finds.
Amid widespread prescription stimulant misuse, new research begins to characterize how pharmaceutical marketing may play a role.
Research highlights opportunity to intervene with adolescents, a group particularly vulnerable to addiction and overdose.
Only 1 in 4 diagnosed youths receives timely treatment with medication for opioid use disorder.